2-氨基-5-溴-3-(羟甲基)吡啶 | 335031-01-1

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基-5-溴-3-(羟甲基)吡啶
• 中文别名: 2-氨基-5-溴-3-吡啶甲醇；(2-氨基-5-溴吡啶-3-基)甲醇；2-氨基-5-溴-3-羟甲基吡啶
• 英文名称: 2-amino-5-bromo-3-(hydroxymethyl)pyridine
• 英文别名: 2-amino-5-bormo-3(hydroxymethyl)pyridine；(2-amino-5-bromo-pyridin-3-yl)-methanol；2-amino-3-hydroxymethyl-5-bromopyridine；(2-amino-5-bromopyridin-3-yl)methanol；2-amino-5-bromo-3-pyridinemethanol
• CAS: 335031-01-1
• 化学式: C₆H₇BrN₂O
• 分子量: 203.038
• InChiKey: HIVQAWXDBPYNDU-UHFFFAOYSA-N

物化性质

• 熔点：
  137-140°C
• 沸点：
  343.5±37.0 °C(Predicted)
• 密度：
  1.766±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Amino-5-bromo-3-(hydroxymethyl)pyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Amino-5-bromo-3-(hydroxymethyl)pyridine
Ingredient name:
CAS number: 335031-01-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H7BrN2O
Molecular weight: 203

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-溴-3-(羟甲基)吡啶 在 氢溴酸 、 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 、 三(邻甲基苯基)磷 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 丙腈 为溶剂， 反应 1.17h， 生成 (E)-3-(1'-methyl-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS
  [FR] NOUVEAUX ACRYLAMIDES HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES

  摘要：

  这项发明涉及新颖的杂环丙烯酰胺化合物（I），涉及该化合物及其中间体的制备，涉及将该化合物用作抗菌药物以及含有该化合物的药物组合物的用途。

  公开号：

  WO2011061214A1
• 作为产物：
  描述：

  2-氨基烟酸 在 lithium aluminium tetrahydride 、 溴 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 生成 2-氨基-5-溴-3-(羟甲基)吡啶
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS
  [FR] NOUVEAUX ACRYLAMIDES HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES

  摘要：

  这项发明涉及新颖的杂环丙烯酰胺化合物（I），涉及该化合物及其中间体的制备，涉及将该化合物用作抗菌药物以及含有该化合物的药物组合物的用途。

  公开号：

  WO2011061214A1

文献信息

• [EN] BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BIARYLAMIDE DE PRODUCTION DE LEUKOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012082817A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中A、B、C、R1a、R1b、R2、R3、R4a和R4b如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• Copper-catalyzed synthesis of pyrido-fused quinazolinones from 2-aminoarylmethanols and isoquinolines or tetrahydroisoquinolines
  作者：Thao T. Nguyen、Khang X. Nguyen、Phuc H. Pham、Duc Ly、Duyen K. Nguyen、Khoa D. Nguyen、Tung T. Nguyen、Nam T. S. Phan

  DOI：10.1039/d1ob00229e

  日期：——

  Pyrido-fused quinazolinones were synthesized via copper-catalyzed cascade C(sp2)–H amination and annulation of 2-aminoarylmethanols with isoquinolines or pyridines. The transformation proceeded readily in the presence of a commercially available CuCl2 catalyst with molecular oxygen as a green oxidant. Moreover, the dehydrogenative cross-coupling of 2-aminoarylmethanols with tetrahydroisoquinolines

  通过铜催化的级联 C(sp 2 )-H 胺化和 2-氨基芳基甲醇与异喹啉或吡啶的环化合成吡啶并稠合的喹唑啉酮。在市售的 CuCl 2催化剂和分子氧作为绿色氧化剂的存在下，转化很容易进行。此外，还探索了 2-氨基芳基甲醇与四氢异喹啉的脱氢交叉偶联，其中 CuBr 表现出比 CuCl 2更高的催化活性. 在优化的反应条件下观察到广泛的底物范围和良好的功能耐受性。通过这种策略可以获得具有生物活性的天然生物碱芸香芸香碱。该协议的显着特点是复杂的杂环结构很容易在一个合成步骤中从容易获得的反应物和催化剂中获得。这种通往吡啶并融合的喹唑啉酮的途径将是对现有协议的补充。
• [EN] BIARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS BIARYLES ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2011022473A1

  公开（公告）日：2011-02-24

  Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导疾病的化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• [EN] OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS À BASE D'OXADIAZOLE DE LA PRODUCTION DES LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012024150A1

  公开（公告）日：2012-02-23

  The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及以下化合物的化合物（I）的公式或其药学上可接受的盐，其中R1-R5如本文所定义。该发明还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
  申请人：BYLOCK Lars Anders

  公开号：US20130195879A1

  公开（公告）日：2013-08-01

  The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 -R 5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

  本发明涉及使用以下化合物的联合疗法（I）的公式： 或其药用可接受盐，其中R1-R5如本文所定义，并且另外包括一种药用活性剂。该发明还涉及包含这些组合物的药物组合物，以及在治疗各种疾病和紊乱中使用这些组合物的方法。